Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Severine Vermeire

Showing results (71-80 of 232) with videos related to

Pageof 24
Sort By:
Journal of Crohn'S & Colitis|March 2, 2019
Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre StudyNiels Vande Casteele, Filip Baert, Sumin Bian, et al.
Inflammatory Bowel Diseases|June 1, 2012
Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitisClémentine Perrier, Gert de Hertogh, Jonathan Cremer, et al.
Gastroenterology|July 10, 2003
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort studySeverine Vermeire, Maja Noman, Gert Van Assche, et al.
Journal of Molecular Medicine (Berlin, Germany)|March 13, 2008
The Crohn's disease susceptibility gene DLG5 as a member of the CARD interaction networkFrauke Friedrichs, Liesbet Henckaerts, Severine Vermeire, et al.
Journal of Crohn'S & Colitis|February 7, 2019
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical TrialsStephen Hanauer, William J Sandborn, Jean-Frederic Colombel, et al.
Inflammatory Bowel Diseases|January 1, 2005
Pancreatic autoantibodies in inflammatory bowel diseaseSofie Joossens, Severine Vermeire, Kristel Van Steen, et al.
Journal of Crohn'S & Colitis|November 1, 2015
Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel DiseaseSeverine Vermeire, Marie Joossens, Kristin Verbeke, et al.
Journal of Crohn'S & Colitis|May 1, 2015
Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease RecurrenceMarc Ferrante, Konstantinos Papamichael, Dana Duricova, et al.
Scandinavian Journal of Gastroenterology|June 17, 2017
Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's diseaseThomas Billiet, Isabelle Cleynen, Vera Ballet, et al.
Clinics and Research in Hepatology and Gastroenterology|May 16, 2024
Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel diseaseSeverine Vermeire, Marla C Dubinsky, Shervin Rabizadeh, et al.
Pageof 24

Showing results (71-80 of 232) with videos related to

Sort By:
Pageof 24
Journal of Crohn'S & Colitis|March 2, 2019
Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre StudyNiels Vande Casteele, Filip Baert, Sumin Bian, et al.
Inflammatory Bowel Diseases|June 1, 2012
Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitisClémentine Perrier, Gert de Hertogh, Jonathan Cremer, et al.
Gastroenterology|July 10, 2003
Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort studySeverine Vermeire, Maja Noman, Gert Van Assche, et al.
Journal of Molecular Medicine (Berlin, Germany)|March 13, 2008
The Crohn's disease susceptibility gene DLG5 as a member of the CARD interaction networkFrauke Friedrichs, Liesbet Henckaerts, Severine Vermeire, et al.
Journal of Crohn'S & Colitis|February 7, 2019
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical TrialsStephen Hanauer, William J Sandborn, Jean-Frederic Colombel, et al.
Inflammatory Bowel Diseases|January 1, 2005
Pancreatic autoantibodies in inflammatory bowel diseaseSofie Joossens, Severine Vermeire, Kristel Van Steen, et al.
Journal of Crohn'S & Colitis|November 1, 2015
Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel DiseaseSeverine Vermeire, Marie Joossens, Kristin Verbeke, et al.
Journal of Crohn'S & Colitis|May 1, 2015
Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease RecurrenceMarc Ferrante, Konstantinos Papamichael, Dana Duricova, et al.
Scandinavian Journal of Gastroenterology|June 17, 2017
Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's diseaseThomas Billiet, Isabelle Cleynen, Vera Ballet, et al.
Clinics and Research in Hepatology and Gastroenterology|May 16, 2024
Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel diseaseSeverine Vermeire, Marla C Dubinsky, Shervin Rabizadeh, et al.
Pageof 24